This post hoc analysis was weighted towards the population in Vietnam because there was only one subject in Bangladesh

who did Cisplatin concentration not receive the 3 doses of PRV on the same day as doses of OPV. The remainder of the infants received some doses of OPV concomitantly with some, but not all, doses of PRV/placebo (data not shown). The immunogenicity of PRV in those Vietnamese subjects who received concomitant doses of OPV and PRV on the same day showed generally lower GMT anti-rotavirus IgA levels (GMT, 143.2 dilution units/mL) compared with those subjects who did not receive doses of OPV with each of the 3 doses of PRV on the same day (GMT, 232.7 dilution units/mL) (Fig. 5A). The same pattern of decreased PD3 SNA GMT level was noted among those who received

PRV and OPV concomitantly compared to those who did not receive the vaccines together (Fig. 5B). However, it is important to highlight that this study was not designed to evaluate the immunogenicity of PRV when administered concomitantly with OPV or to evaluate the immunogenicity of PRV when not administered concomitantly with OPV. These comparisons are purely observational because these two groups were not randomized accordingly; the group of subjects who did not receive PRV concomitantly with OPV cannot serve as a true control group for those subjects who received PRV and OPV concomitantly. The Talazoparib concentration groups also differ considerably in size. It is important to note that the subjects who did not receive OPV concomitantly (on the same day) may have actually received

OPV one or two days before or after administration of PRV. Administration of OPV one or two days before the administration of the rotavirus vaccine can potentially interfere more with the replication of the rotavirus vaccine than when OPV and the rotavirus vaccine are given on the same day, due to the active replication of the poliovirus vaccine strains. The clinical trial of PRV conducted in Bangladesh and Vietnam is the only Phase III study evaluating the efficacy Levetiracetam and immunogenicity of a rotavirus vaccine performed in GAVI-eligible countries in Asia [14]. Our study allowed the evaluation of the immunogenicity of PRV, an oral vaccine, in infants in two lower socio-economic countries in Asia. In the present study, nearly 88% of the infants showed a ≥3-fold rise in serum anti-rotavirus IgA response. However, the anti-rotavirus IgA seroresponse rates appeared different between the two countries: the rate was approximately 78% and 97% in Bangladesh and Vietnam, respectively, likely reflecting the different socio-economic conditions between the subjects from each of these two GAVI-eligible countries.